ArticleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2021
Estimated GFR Variability and Risk of Cardiovascular Events and Mortality in SPRINT (Systolic Blood Pressure Intervention Trial).
Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Kidney function and brain health: cognitive and structural signatures across cohorts.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Association of cardiovascular risk scores with coronary plaque and its progression among individuals with family history of coronary artery disease.American journal of preventive cardiology · 2026Article
- Article
- Estimated Glomerular Filtration Rate Variability in Patients with Diabetes Receiving SGLT2 Inhibitors Versus DPP4 Inhibitors.Pharmaceutics · 2025Article
- Serum lncRNA-ANRIL and creatinine clearance as cardiovascular risk factors in patients who underwent sleeve gastrectomy.Scientific reports · 2025Article
- Time-Updated Estimated GFR Variability Is Associated With Mortality, Cardiovascular Disease, and End-Stage Kidney Disease in Patients With CKD: Findings From the CRIC Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025Article
- Temporal variations in and predictive values of ABG results prior to in-hospital cardiac arrest.Journal of medicine, surgery, and public health · 2024Article
- Impact of renal function variability on long-term prognosis in ischemic stroke patients with atrial fibrillation.Frontiers in neurology · 2024Article
- Genetics of longitudinal kidney function in children and adults with systemic lupus erythematosus.Rheumatology (Oxford, England) · 2023Article
- Interpreting Estimated GFR Variability and Its Clinical Significance.Kidney medicine · 2023Article
- GFR Variability, Survival, and Cardiovascular Events in Older Adults.Kidney medicine · 2023Article
- Correlation Between Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms and Renal Function in Elderly Men Aged 80 Years and Older.Clinical interventions in aging · 2023Article
- Nomogram to predict rapid kidney function decline in population at risk of cardiovascular disease.BMC nephrology · 2022Article
- The roles of sodium and volume overload on hypertension in chronic kidney disease.Kidney research and clinical practice · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
RATIONALE AND
objectiveAlthough low estimated glomerular filtration rate (eGFR) is associated with cardiovascular disease (CVD) events and mortality, the clinical significance of variability in eGFR over time is uncertain. This study aimed to evaluate the associations between variability in eGFR and the risk of CVD events and all-cause mortality. STUDY
designLongitudinal analysis of clinical trial participants. SETTINGS AND
participants7,520 Systolic Blood Pressure Intervention Trial (SPRINT) participants ≥50 year of age with 1 or more CVD risk factors. PREDICTORS: eGFR variability, estimated by the coefficient of variation of eGFR assessments at the 6th, 12th, and 18-month study visits. OUTCOMES: The SPRINT primary CVD composite outcome (myocardial infarction, acute coronary syndrome, stroke, heart failure, or CVD death) and all-cause mortality from month 18 to the end of follow-up. ANALYTICAL APPROACH: Cox models were used to evaluate associations between eGFR variability and CVD outcomes and all-cause mortality. Models were adjusted for demographics, randomization arm, CVD risk factors, albuminuria, and eGFR at month 18.
resultsMean age was 68 ± 9 years; 65% were men; and 58% were White. The mean eGFR was 73 ± 21 (SD) mL/min/1.73 m LIMITATIONS: Persons with diabetes and proteinuria > 1 g/d were excluded.
conclusionsIn trial participants at high risk for CVD, greater eGFR variability was independently associated with all-cause mortality but not CVD events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.